Moderna is a company in the middle of a painful but telling transition. After generating nearly $20 billion in revenue at the peak of COVID-19 vaccine demand in 2021–2022, its top line has collapsed as that tailwind faded — falling to under $2 billion in fiscal 2025. The company has been burning cash heavily, posting deep operating losses for three consecutive years. However, the most recent quarterly data (Q3 2026) offers the first meaningful sign of a turn: Moderna posted a small but real operating profit, suggesting the aggressive cost-cutting and pipeline progress may finally be stabilizing the business. The balance sheet remains reasonably solid with a current ratio above 3.6x and very low debt, giving it a runway to pursue its broad mRNA pipeline. The core question for investors is whether new products — RSV, flu, and other candidates — can rebuild a durable revenue base before the cash cushion erodes too far.
Snapshot & Big Picture
Moderna's financial story over the last decade is essentially three chapters: a pre-revenue biotech (2016–2020) burning cash to build its mRNA platform; a brief but extraordinary profit bonanza driven entirely by the COVID-19 vaccine Spikevax (2021–2022); and a post-COVID contraction (2023–present) as that revenue evaporated and the company invested heavily to diversify its pipeline. The challenge now is bridging from a one-product company back to a sustainable multi-product business. Capital allocation, cost discipline, and pipeline execution are the variables that will determine whether Moderna re-rates as a durable biopharma or remains a cautionary tale of boom-and-bust single-product dependence.
| Fiscal Year | Revenue | EBITDA | Operating Margin | Net Margin |
|---|---|---|---|---|
| 2016 | $108M | -$209M | -206.4% | -199.5% |
| 2017 | $206M | -$249M | -130.9% | -124.3% |
| 2018 | $135M | -$388M | -306.0% | -284.8% |
| 2019 | $60M | -$515M | -906.8% | -853.7% |
| 2020 | $803M | -$732M | -95.0% | -93.0% |
| 2021 | $18.5B | $13.5B | +72.0% | +66.1% |
| 2022 | $19.3B | $9.8B | +48.9% | +43.4% |
| 2023 | $6.8B | -$3.6B | -61.9% | -68.8% |
| 2024 | $3.2B | -$3.8B | -121.9% | -110.0% |
| 2025 | $1.9B | -$2.9B | -158.1% | -145.2% |
Latest Quarter Snapshot
The Q3 2026 results (period ending September 30, 2026, filed November 2026) are the most current data available and represent a more up-to-date picture than the annual figures above. For the quarter, Moderna reported revenue of $1.313 billion — a meaningful number on its own, suggesting the annualized run rate has recovered compared to full-year 2025. More importantly, the company swung to a positive operating margin of +9.9% and a positive net margin of +12.3%, producing EBITDA of $191 million. This is the first quarter of evident profitability in several years and may signal that cost restructuring and modest pipeline launches are beginning to take hold. The current ratio stood at 3.62x, and the debt-to-equity ratio remained very low at 0.086, indicating a stable near-term liquidity position.
Profitability
Moderna's profitability history is volatile by any measure. The company was deeply unprofitable from 2016 through 2020 as a pre-commercial mRNA platform business, then swung to extraordinary profitability in 2021 and 2022 on the back of Spikevax, with operating margins peaking near 72% in 2021. The collapse that followed was steep: by 2023 the operating margin had turned to -61.9%, worsening to -121.9% in 2024 and -158.1% in 2025 as revenue fell much faster than operating expenses. Gross margin data was not available in the filings provided across any of the annual periods. The Q3 2026 quarterly result — a positive operating margin of +9.9% — is the most encouraging data point in the recent trend and suggests the cost restructuring program announced in prior years is beginning to show results. Whether this is the start of a durable recovery or a seasonal blip will depend on the cadence of new product approvals and commercial uptake.
Financial Health
Moderna's balance sheet has held up better than its income statement during the downturn. The current ratio has remained above 2.7x in every annual period since 2022 and improved to 3.62x in Q3 2026, indicating comfortable short-term liquidity. Debt has been remarkably low throughout — the debt-to-equity ratio was essentially zero in 2024, rising only slightly to 0.086 in the most recent quarter. This means the losses have been funded primarily by drawing down the cash and investment reserves accumulated during the 2021–2022 profit peak rather than by taking on debt.
Capital expenditures tell an interesting story about investment intensity. During the COVID peak years, capex was modest relative to revenue: $284M (1.5% of revenue) in 2021 and $400M (2.1%) in 2022, as the business was generating cash faster than it could deploy it into infrastructure. As revenue declined, Moderna sharply increased absolute capex — $707M (10.3% of revenue) in 2023 and a striking $1.051 billion (32.5% of revenue) in 2024 — reflecting heavy investment in manufacturing capacity and pipeline infrastructure at exactly the moment cash flows turned negative. This is a high-risk capital posture: spending aggressively on future capacity while the core business shrinks. In 2025, capex pulled back materially to $192M (9.9% of revenue), suggesting the company shifted to capital preservation mode. The Q3 2026 quarter shows capex of $62M (4.7% of revenue), consistent with a leaner spending posture. The overall trajectory — a spike in capital intensity in 2023–2024 followed by deliberate retrenchment — reflects a company that overbuilt during the transition and is now rightsizing. Future capital needs will depend heavily on how many pipeline candidates advance to commercialization and whether Moderna pursues manufacturing expansion or opts for partnerships.
Growth
The revenue CAGR figures below capture just how dramatically Moderna's growth profile has shifted depending on the measurement window.
| Window | Start Year | End Year | Start Revenue | End Revenue | CAGR |
|---|---|---|---|---|---|
| 3-Year | FY 2022 | FY 2025 | $19.3B | $1.9B | -53.4% |
| 5-Year | FY 2020 | FY 2025 | $803M | $1.9B | +19.3% |
| 10-Year | N/A | N/A | N/A | N/A | Not available — insufficient filing history extending back a full 10 fiscal years from 2025 |
The 3-year CAGR of -53.4% is one of the starkest revenue contractions in large-cap biopharma history, driven entirely by the normalization of COVID vaccine demand from an extraordinary peak. The 5-year CAGR of +19.3% offers a more structurally honest picture, capturing the full arc from pre-vaccine commercial revenues through the boom and back down — and showing that even after the collapse, Moderna is a larger revenue business today than it was in 2020. The 10-year window is not available because the company's SEC filing history does not extend back a full decade from fiscal year 2025. Together, these figures underscore that the near-term growth challenge is severe, but the starting point for any recovery is not zero — it is a small but real commercial base that the Q3 2026 results suggest may be starting to rebuild.

Leave a Comment